← All trials
NCT02742467
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2016
- Primary completion
- Sep 1, 2018
- Completion date
- Jun 1, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 702
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- University of AbujaLead sponsor
- University of AbujaReponsible party - principal investigator
- University of Cape TownStudy chair
- University of LondonStudy director
- University of Cape TownCollaborator
- University of NairobiCollaborator
- University of IbadanCollaborator
- University of LondonCollaborator
- Hospital General De DoualaCollaborator
- Mulago Hospital, UgandaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.